The Manufacturers Life Insurance Company Lowers Position in Heartflow, Inc. $HTFL

The Manufacturers Life Insurance Company trimmed its stake in shares of Heartflow, Inc. (NASDAQ:HTFL) by 47.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 19,227 shares of the company’s stock after selling 17,650 shares during the period. The Manufacturers Life Insurance Company’s holdings in Heartflow were worth $468,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new stake in Heartflow in the 4th quarter worth $27,000. Russell Investments Group Ltd. purchased a new position in shares of Heartflow during the fourth quarter valued at about $45,000. Legal & General Group Plc purchased a new position in shares of Heartflow during the third quarter valued at about $59,000. Strs Ohio bought a new stake in shares of Heartflow in the fourth quarter worth about $99,000. Finally, Bessemer Group Inc. purchased a new stake in shares of Heartflow in the first quarter worth about $126,000.

Heartflow News Roundup

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
• Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
• Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
• Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
• Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Wall Street Analysts Forecast Growth

HTFL has been the subject of several research analyst reports. Stifel Nicolaus raised their price target on Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday. JPMorgan Chase & Co. upped their price objective on Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday. Canaccord Genuity Group increased their target price on Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Friday. Robert W. Baird set a $45.00 target price on shares of Heartflow in a report on Friday. Finally, Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Heartflow currently has a consensus rating of “Moderate Buy” and an average target price of $43.43.

Heartflow Trading Up 35.7%

Shares of NASDAQ:HTFL opened at $42.08 on Friday. The company has a market cap of $3.63 billion and a price-to-earnings ratio of -22.99. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $43.00. The company has a 50-day moving average price of $29.08 and a 200 day moving average price of $27.80.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.50% and a negative net margin of 55.82%.The company had revenue of $64.08 million for the quarter. Heartflow’s quarterly revenue was up 47.7% compared to the same quarter last year. As a group, equities analysts forecast that Heartflow, Inc. will post -0.82 EPS for the current year.

Insider Buying and Selling

In other news, insider Campbell Rogers sold 9,219 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $28.34, for a total transaction of $261,266.46. Following the transaction, the insider owned 78,731 shares of the company’s stock, valued at approximately $2,231,236.54. The trade was a 10.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 38,900 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total value of $1,361,500.00. Following the sale, the chief executive officer owned 457,935 shares in the company, valued at $16,027,725. The trade was a 7.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 115,805 shares of company stock valued at $3,530,609. Company insiders own 7.70% of the company’s stock.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.